Cerebral hemisphere lipoma

Summary

Cerebral hemisphere lipoma (MONDO:0003843) is a disease. A subtype of central nervous system lipoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cerebral hemisphere lipoma
Mondo ID	MONDO:0003843
DOID	DOID:6291
NCIT	C6220
UMLS	C1332907
MedGen	234111
Anatomy (UBERON)	UBERON:0001869
Is cancer (heuristic)	no

Also known as: cerebral hemisphere lipoma · lipoma of cerebral hemisphere · lipoma of the cerebral hemisphere

Disease family

This is a subtype of central nervous system lipoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › nervous system benign neoplasm › central nervous system organ benign neoplasm › central nervous system lipoma › cerebral hemisphere lipoma

Related subtypes (2): spinal cord lipoma, central nervous system hibernoma

Subtypes (1): corpus callosum lipoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.